[EXPERIENCE IN ORGANIZING THE WORK OF THE CENTER FOR PERSONALIZED TREATMENT OF MALIGNANT NEOPLASMS (NETHERLANDS)].
| Autor: | Andreev DA; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department., Zavyalov AA; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department.; Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. |
|---|---|
| Jazyk: | ruština |
| Zdroj: | Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny [Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med] 2022 Dec 15; Vol. 30 (s1), pp. 961-965. Date of Electronic Publication: 2022 Dec 15. |
| DOI: | 10.32687/0869-866X-2022-30-s1-961-965 |
| Abstrakt: | Introduction: In the last decade, there has been a «breakthrough» development of scientific approaches to the assay of genomic and immune factors underlying anti-cancer treatment efficiency. The choice of antitumor therapy in practice is increasingly determined by molecular signatures, and not only by the specificity of organ tumor originated from (or by the histological properties of the tumor). An urgent and important scientific and practical task is to study the successful experience of organizing Centers for Personalized Cancer Treatment (CPCT). Aim: analysis of the 10-year experience of the Clinical Center for Personalized Cancer Treatment in the Netherlands. Materials and Methods: Data were extracted from the internet databases using keywords: personalized cancer therapy / treatment, cancer, targeted therapy etc.Results. The Center's research project collects data on patients with metastatic cancer who are eligible for anticancer treatment as part of standard practice. The system accumulates various information about tumor DNA, mutations and abnormalities in DNA, treatment results (outcomes), as well as other important clinical characteristics, including individual tumor process. Registered parameters are stored in a digital database and are available for scientific research. Discussion and Conclusions: CPCT consider the possibilities for the more in-depth genomic analysis of patient DNA (including non-tumor DNA) in the future in order to improve the medical decision making regarding early diagnosis and personalized choice of anticancer therapies. Rapid progress will lead to the emergence of more advanced methods for re-evaluating biological samples accumulated in biobanks, that will facilitate the understanding the pillars of personalized anti-cancer treatment approaches as well as create an additional bases for the new drug development. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|